Capsaicin 8% patch is cost-effective compared to pregabalin for patients who have failed one or more previous systemic treatments for PNP.
Objectives: The objective of the analysis was to evaluate costs and outcomes of treating post-herpetic neuralgia (PHN), a chronic disease with severe burden for patients, in the Netherlands with lidocaine 5% medicated plaster compared to pregabalin and amitriptyline. MethOds: A Markov model was used to extrapolate outcomes beyond the time horizon of the available trial data and to allow for the fact that patients may discontinue treatment at any point during treatment. Costs and effects, expressed in terms of the quality-adjusted life-year (QALY) gained, were calculated for each treatment strategy over a period of 6 months. The study included direct costs related to PHN. Indirect costs were not included as most patients with PHN are older and retired. Transition probabilities were based on the comparative and long-term clinical trials. Utilites were identified through a literature review. Resource utilization was obtained from a two-step Delphi study with pain specialists, cost data were obtained from the official price tariffs/lists. Extensive sensitivity and scenario analyses were performed to explore robustness of the results. Results: In 6-month time horizon, treatment with the lidocaine plaster yielded 0.4283 QALYs. For pregabalin and amitriptyline the total effect was 0.3390 QALYs. The mean costs per patient treated with lidocaine plaster (1.71 plasters/day) were 1,082 € . For pregabalin (488 mg/day) and amitriptyline (25 mg/day) the mean costs were 912 € and 346 € , respectively. Therefore, the lidocaine plaster compared to pregabalin and amitriptyline had an incremental cost-effectiveness ratio of 1,907 € /QALY and 8,246 € /QALY, respectively. Probability of the lidocaine plaster being cost-effective versus pregabalin and amitriptyline exceeded 90% when considering a threshold of 30,000 € per QALY gained. Extensive scenario and one-way sensitivity analyses confirmed robustness of the results. cOnclusiOns: The lidocaine 5% plaster is a highly cost-effective treatment for PHN in the Netherlands. Objectives: The main objective was to perform a pharmacoeconomic analysis to find out the cost effectiveness of diethylpropion (DEP) with diet and exercise. (DEP+DaE), compared against Diet and Exercise (DaE) in the treatment for obesity from the institutional point of view in Mexico. MethOds: Effectiveness data from a mexican clinical trial (Morin, 2007) was used to populate a decision tree model to estimate the cost-effectiveness of DEP+DaE and its comparator DaE. The target population were men and women over 18 years with BMI > 30 kg/m2. Principal outcome was the reduction of the Body Mass Index (BMI); benefit was expressed as the percentage of patients who reduced more than 10% of their initial weight. Only direct medical costs were used, such as medications and adverse events; these were obtained from the portal shop by IMSS and also from their unitary costs. To prove the Years Gained -LYG) and cost-utility analysis (Quality-Adjusted Life years -QALYs) were performed for a time horizon of 10 years according to a Markov economic model with four health states -"progression free survival (PFS) in first and second lines", "progression" and "death" -and monthly cycles. Health states transition probabilities were obtained from two randomized controlled clinical trials: PRIMA (Salles G. et al 2010) and EORTC 20981 (van Oers M. et al 2010) . Health state utilities were obtained from literature (Pettengell R. et al 2008) . Resource consumption was estimated by a Portuguese expert's panel. Costs were calculated considering the Portuguese Health System perspective through official data (unit costs: € in 2014). Costs and consequences were discounted at 5% per annum. Deterministic and probabilistic (Monte Carlo simulation) sensitivity analyses were performed for several assumptions namely time horizon, PFS supportive care and progression costs; adverse events costs; health states utilities values and costs and benefits annual discount. Results: For a 10 years' time horizon, the cost per LYG and QALYs gained was € 10,630 and € 10,674 respectively. Sensitivity analyses confirmed the base case results for time horizons of 20 and 30 years, ranging between € 7,430 and € 7,155 per QALY gained, respectively. Probabilistic sensitivity analysis confirmed the robustness of the model with a cost per QALY gained of € 10,657. The incremental cost-effectiveness acceptability curve shows that rituximab maintenance therapy would be cost effective from a willingness to pay of € 12,000 per QALY gained. cOnclusiOns: According to the present model rituximab maintenance treatment of FL patients who respond to first line induction therapy compared with observation is a cost-effective strategy in Portugal. Objectives: The NHS newborn bloodspot screening programme currently screens all babies in England for five rare conditions. The objective of this study was to assess the cost-effectiveness of expanding the screening programme to include five new rare conditions all inborn errors of the metabolism; HCU, MSUD, GA1, IVA, and LCHADD. MethOds: A decision tree model was built to estimate the cost-effectiveness of the expanded newborn screening programme. Estimates of the prevalence of the five conditions and the test characteristics of screening were taken from the literature. Survival and morbidity estimates for the screened and unscreened populations were estimated from published case series. Quality adjusted life years (QALYS) were estimated from the extended EQ-5D+ (C) which includes a cognitive dimension in order to capture the impact of neurological impairment and developmental delay which are known sequelae of the five conditions. Costs related to the marginal cost of the expanded screening programme, management costs of the conditions, and costs associated with the sequelae of the conditions were estimated from the pilot study of the expanded screening, case reports from the pilot, expert elicitation, published guidelines and estimates from the literature. Costs and QALYs were multiplied by survival and morbidity estimates to give lifetime estimates for the screened and unscreened populations. A probabilistic sensitivity analysis (PSA) was conducted. Results: The results from the deterministic analysis and PSA suggests that screening for all five conditions is cost-saving with screening associated with lower total costs and higher total QALYs compared to no screening. The incremental net benefit for all five conditions, at a threshold of £25,000 per QALY, was between £0.46 for IVA and £5.94 for GA1. cOnclusiOns: Screening for MSUD, HCU, IVA, GA1 and LCHADD are each estimated to be potentially cost saving and result in increased quality of life compared to no screening.
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